The Trump administration has filed its response to a request for a preliminary injunction in a case involving the Department of Defense's decision to designate a Chinese biotech company as a "Chinese Military Company."

Last week, Chinese e-commerce giant Alibaba and its U.S. payment processor agreed to pay $600 million to settle U.S. government allegations that they let merchants use their platforms to smuggle illegal pharmaceuticals and pill presses into the United States.

In a filing earlier this week, a Chinese tech company laid out its case for an injunction in relation to a Trump administration decision to designate it as a "Chinese Military Company," focusing on first amendment speech issues.

In a filing earlier this week, a Chinese biotech company laid out its case for asking a court to enjoin a Trump administration decision to designate it as a "Chinese Military Company."

Adding to the growing list of complaints against the designation of companies as a "Chinese Military Company" (CMC), tech giant Alibaba has filed a lawsuit against the Trump administration in federal district court in the Northern District of California, challenging the designation made earlier this month.

In the third lawsuit of its kind filed against Washington’s national security blacklists, global pharmaceutical and life sciences giant WuXi AppTec Co., Ltd. has filed a federal lawsuit challenging its designation as a "Chinese Military Company" (CMC).

In an order issued today, the U.S. Supreme Court declined to hear an appeal related to the Section 301 tariffs originally imposed on Chinese imports during President Trump's first term. This leaves the appeals court decision in the case as the final word on the matter for